CombiGene AB (LARK) AI Stock Analysis

• Market Cap: kr44.55M
• Dividend Yield: 8.47%
• Average Volume (3M): 41.41K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: -94.12%
• EPS Growth: -25.83%
• Country: SE
• Employees: 9
• Sector: Financial
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,801,197
• 10 Day Avg. Volume: 70,026
• 30 Day Avg. Volume: 41,406
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: kr2.00 ▼(-14.89% Downside)

The score is held down primarily by deteriorating financial performance (sharp revenue decline, widening losses, and continued cash burn), partially offset by a low-leverage/debt-free balance sheet. Technical indicators also reflect weak momentum, while valuation support is limited by a loss-making P/E despite a high stated dividend yield.

Positive Factors

Debt-Free Balance Sheet

A debt-free balance sheet reduces financial risk and refinancing pressure, providing flexibility for future strategic investments.

Gene-Therapy Focus

The focus on gene-therapy for neurological diseases positions the company in a high-potential market with growing demand for innovative treatments.

Cash Flow Tracking

Close tracking of cash flow to net income indicates efficient cash management, which is crucial for sustaining operations during loss-making periods.

Negative Factors

Revenue Decline

A sharp decline in revenue indicates challenges in maintaining sales momentum, which could hinder long-term growth and market competitiveness.

Sustained Cash Burn

Sustained cash burn reflects ongoing financial strain, potentially limiting the company's ability to invest in R&D and future growth initiatives.

Equity Decline

A decline in equity suggests value erosion, which could impact investor confidence and the company's ability to raise capital in the future.

CombiGene AB Business Overview & Revenue Model

Company Description

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

How the Company Makes Money

CombiGene makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue by partnering with larger pharmaceutical companies for the co-development, licensing, and distribution of its therapies. These partnerships often include upfront payments, milestone payments, and royalties on sales. Additionally, CombiGene may secure funding from grants and research collaborations with academic institutions and research organizations, which support the advancement of its therapeutic programs.

CombiGene AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

CombiGene AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Negative. The current price of 2.35 is above the 20-day moving average (MA) of 2.33, below the 50-day MA of 2.39, and below the 200-day MA of 2.37, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.29 is Neutral, neither overbought nor oversold. The STOCH value of 28.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LARK.

CombiGene AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
2CUREX	53 Neutral	kr41.42M	-7.96	-304.59%	11.26%	―	―
SPRINT	49 Neutral	kr159.86M	-5.03	-264.12%	―	-17.80%	-11.96%
EXPRS2	46 Neutral	kr55.99M	-0.87	-88.65%	―	8.46%	11.73%
LARK	43 Neutral	kr44.55M	-0.99	―	8.47%	-94.12%	-25.83%
STABL	42 Neutral	kr14.61M	-1.33	-91.33%	―	―	64.02%
LIDDS	40 Underperform	kr1.77M	-0.32	-132.58%	―	―	86.26%